GENimmune NV

GENimmune NV is a newly created biopharmaceutical company, based in Belgium, that focuses on developing immune therapeutics against chronic infectious diseases characterized by inadequate immune responses. The company has already developed an early-stage pipeline of therapeutic vaccine candidates against the hepatitis B and C viruses and human papillomavirus. GENimmune's goal is to optimize the human immune response through rational vaccine design. Its vaccine-development strategy is based on the use of polyepitopes that take immunological plasticity and viral diversity into account. This represents an original approach to medical treatment. The company's R&D activities are supported by a biomanufacturing unit that also has an established track record of providing customized third-party contract services.